Moreover, we have identified DDIT3 as a key TF involved in the pathogenesis of abnormal erythropoiesis in MDS, thus, representing a potential therapeutic target to restore the inefficient erythroid differentiation of these patients. This evidence concerns the gene DDIT3 and myelodysplastic syndrome.